Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Q. Mei
Pd-1 Inhibitor Plus Chemotherapy in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl) With Aggressive Bulky Disease
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Early, Selective, and Marked Loss of Sympathetic Nerves From the Islets of BioBreeder Diabetic Rats
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Related publications
Primary Mediastinal Large B-Cell Lymphoma
Oncologist
Cancer Research
Medicine
Oncology
PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-Cell LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) ± RADIOTHERAPY (RT)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Primary Mediastinal Large B-Cell Lymphoma During Pregnancy
Case Reports in Hematology
Primary Mediastinal Large B-Cell Lymphoma-The Role of Mediastinal Radiation
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma
American Journal of Hematology
Hematology
Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
New England Journal of Medicine
Medicine
Extranodal Diffuse Large B-Cell Lymphoma With Monoclonal Gammopathy: An Aggressive and Primary Refractory Disease Responding to an Immunomodulatory Agent
Experimental Hematology and Oncology
Cancer Research
Oncology
Hematology
The Dial Study (Dual Immunomodulation in Aggressive Lymphoma): Randomized Phase 2 Trial of Varlilumab Plus Nivolumab in Relapsed/Refractory Aggressive B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
